FR22C1047I2 - Derives de benzimidazole-proline - Google Patents

Derives de benzimidazole-proline

Info

Publication number
FR22C1047I2
FR22C1047I2 FR22C1047C FR22C1047C FR22C1047I2 FR 22C1047 I2 FR22C1047 I2 FR 22C1047I2 FR 22C1047 C FR22C1047 C FR 22C1047C FR 22C1047 C FR22C1047 C FR 22C1047C FR 22C1047 I2 FR22C1047 I2 FR 22C1047I2
Authority
FR
France
Prior art keywords
benzimidazole
proline derivatives
proline
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1047C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of FR22C1047I1 publication Critical patent/FR22C1047I1/fr
Application granted granted Critical
Publication of FR22C1047I2 publication Critical patent/FR22C1047I2/fr
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR22C1047C 2012-06-04 2022-09-13 Derives de benzimidazole-proline Active FR22C1047I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12170748 2012-06-04
EP13158520 2013-03-11
PCT/IB2013/054567 WO2013182972A1 (en) 2012-06-04 2013-06-03 Benzimidazole-proline derivatives
EP13744805.6A EP2855453B1 (en) 2012-06-04 2013-06-03 Benzimidazole-proline derivatives

Publications (2)

Publication Number Publication Date
FR22C1047I1 FR22C1047I1 (fr) 2022-10-14
FR22C1047I2 true FR22C1047I2 (fr) 2023-08-18

Family

ID=48914370

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1047C Active FR22C1047I2 (fr) 2012-06-04 2022-09-13 Derives de benzimidazole-proline

Country Status (33)

Country Link
US (3) US9732075B2 (zh)
EP (1) EP2855453B1 (zh)
JP (1) JP5814491B2 (zh)
KR (3) KR101689093B1 (zh)
CN (1) CN104334544B (zh)
AR (1) AR091257A1 (zh)
AU (1) AU2013273222B2 (zh)
BR (1) BR112014030173B1 (zh)
CA (1) CA2873341C (zh)
CL (1) CL2014003294A1 (zh)
CY (1) CY1118735T1 (zh)
DK (1) DK2855453T3 (zh)
EA (2) EA029899B1 (zh)
ES (1) ES2617863T3 (zh)
FR (1) FR22C1047I2 (zh)
HK (1) HK1208449A1 (zh)
HR (1) HRP20170351T1 (zh)
HU (2) HUE031753T2 (zh)
IL (1) IL236024A (zh)
LT (2) LT2855453T (zh)
MX (1) MX354102B (zh)
MY (1) MY169986A (zh)
NL (1) NL301197I2 (zh)
NO (1) NO2022044I1 (zh)
NZ (1) NZ703448A (zh)
PH (1) PH12014502540A1 (zh)
PL (1) PL2855453T3 (zh)
PT (1) PT2855453T (zh)
SG (2) SG11201408004SA (zh)
SI (1) SI2855453T1 (zh)
TW (2) TWI570120B (zh)
WO (1) WO2013182972A1 (zh)
ZA (1) ZA201409422B (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5744203B2 (ja) 2010-08-24 2015-07-08 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd オレキシン受容体拮抗薬としてのプロリンスルフォンアミド誘導体
EP2855453B1 (en) 2012-06-04 2016-12-07 Actelion Pharmaceuticals Ltd. Benzimidazole-proline derivatives
WO2014057435A1 (en) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
CA2902135A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
MX363432B (es) 2013-07-22 2019-03-22 Idorsia Pharmaceuticals Ltd Derivados 1-(piperazin-1-il)-2-([1,2,4]triazol-1-il)-etanona.
MA39163B1 (fr) * 2013-12-03 2018-09-28 Idorsia Pharmaceuticals Ltd Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
UA119151C2 (uk) * 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
JP6421185B2 (ja) * 2013-12-04 2018-11-07 イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd ベンゾイミダゾール−プロリン誘導体の使用
TW201613864A (en) * 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
CN106164064B (zh) * 2014-02-20 2019-03-22 武田药品工业株式会社 作为阿立新受体拮抗剂的取代环戊烷、四氢呋喃和吡咯烷
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
RS58349B1 (sr) * 2015-01-15 2019-03-29 Idorsia Pharmaceuticals Ltd Hidroksialkil-piperazinski derivati kao modulatori cxcr3 receptora
US10196383B2 (en) 2015-07-17 2019-02-05 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
KR20180058815A (ko) 2015-10-01 2018-06-01 바이오크리스트파마슈티컬즈,인코포레이티드 인간 혈장 칼리크레인 저해제
SG11201804223TA (en) 2015-11-23 2018-06-28 Sunshine Lake Pharma Co Ltd OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
DK3619199T3 (da) 2017-05-03 2021-09-27 Idorsia Pharmaceuticals Ltd Fremstilling af 2-([1,2,3]triazol-2-yl)-benzoesyrederivater
WO2019002344A1 (en) 2017-06-29 2019-01-03 Lonza Guangzhou Nansha Ltd. PROCESS FOR THE PREPARATION OF ALPHA-METHYL-L-PROLINE
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020007977A1 (en) 2018-07-06 2020-01-09 Idorsia Pharmaceuticals Ltd 7-trifluoromethyl-[1,4]diazepan derivatives
CN108997308A (zh) * 2018-07-09 2018-12-14 西藏大学 一种苯并咪唑类衍生物及其制备方法和应用
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
AU2021260018A1 (en) 2020-04-19 2022-12-22 Idorsia Pharmaceuticals Ltd Medical use of daridorexant
EP4289834A1 (en) * 2021-02-02 2023-12-13 Medshine Discovery Inc. Tetrahydropyrrolocyclic compound and application thereof
CN115925699B (zh) * 2022-02-25 2023-10-03 南京知和医药科技有限公司 具有镇痛活性的稠环化合物及其制备方法与用途
TW202400149A (zh) 2022-05-13 2024-01-01 瑞士商愛杜西亞製藥有限公司 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物
CN117736193A (zh) * 2023-12-19 2024-03-22 南京知和医药科技有限公司 一种氘代稠环化合物及其制备方法与用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282927A (en) 1964-05-21 1966-11-01 Bristol Myers Co 5-phenyl-4-thiazolylpenicillins
AUPQ253199A0 (en) 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist
AU2001272476A1 (en) 2000-06-16 2001-12-24 Smithkline Beecham Plc Piperidines for use as orexin receptor antagonists
US20030055037A1 (en) 2000-10-06 2003-03-20 Delombaert Stephane Benzimidazole and indole derivatives as CRF receptor modulators
US6943160B2 (en) 2000-11-28 2005-09-13 Smithkline Beecham Plc Morpholine derivatives as antagonists of orexin receptors
JP4309135B2 (ja) 2001-05-05 2009-08-05 スミスクライン ビーチャム ピー エル シー N−アロイルサイクリックアミン
AU2002341123A1 (en) 2001-05-05 2002-11-18 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
DE60212968T2 (de) * 2001-06-28 2007-02-01 Smithkline Beecham P.L.C., Brentford N-aroyl-(cyclisches amin)-derivate als orexinrezeptor antagonisten
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
DE10240818A1 (de) 2002-08-30 2004-05-13 Grünenthal GmbH Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
WO2004026866A1 (en) 2002-09-18 2004-04-01 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
AR044586A1 (es) 2003-06-04 2005-09-21 Aventis Pharma Sa Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
SI1751111T1 (sl) 2004-03-01 2015-04-30 Actelion Pharmaceuticals Ltd. Substituirani 1,2,3,4-tetrahidroizokinolinski derivati
WO2005113522A1 (en) 2004-05-07 2005-12-01 Janssen Pharmaceutica, N.V. Azole carboxamide inhibitors of bacterial type iii protein secretion systems
EP1604989A1 (en) 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
GB0510142D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
HUP0500920A2 (en) 2005-10-05 2007-07-30 Richter Gedeon Nyrt Oxadiazole derivatives, process for their preparation and their use
EA015256B1 (ru) 2006-03-15 2011-06-30 Актелион Фармасьютикалз Лтд. Производные тетрагидроизохинолина для повышения функции памяти
WO2008008517A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
BRPI0715893A2 (pt) 2006-08-15 2013-09-17 Actelion Pharmaceuticals Ltd composto de azetidina e uso para a preparaÇço de um medicamento para a prevenÇço ou tratamento de distérbios distÍmicos ou do sono
TW200823227A (en) 2006-09-29 2008-06-01 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
US8124623B2 (en) 2006-11-10 2012-02-28 Actelion Pharmaceuticals Ltd. 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CL2007003827A1 (es) 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
WO2008087611A2 (en) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Pyrrolidine- and piperidine- bis-amide derivatives
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
US20100222328A1 (en) 2007-05-14 2010-09-02 Hamed Aissaoui 2-cyclopropyl-thiazole derivatives
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2008260647A1 (en) 2007-05-23 2008-12-11 Merck Sharp & Dohme Corp. Cyclopropyl pyrrolidine orexin receptor antagonists
PE20090441A1 (es) 2007-07-03 2009-05-08 Glaxo Group Ltd DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
BRPI0813218A2 (pt) 2007-07-03 2014-12-23 Actelion Pharmaceuticals Ltd Composto, composição farmacêutica que o contém como princípio ativo e uso do composto.
US7751938B2 (en) 2007-07-05 2010-07-06 Panasonic Corporation Robot arm control device and control method, robot, and control program
AR067665A1 (es) 2007-07-27 2009-10-21 Actelion Pharmaceuticals Ltd Derivados de trans-3- aza-biciclo ( 3.1.0) hexano
WO2009016564A2 (en) 2007-07-27 2009-02-05 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.3.0]octane derivatives
ATE493386T1 (de) 2007-07-27 2011-01-15 Actelion Pharmaceuticals Ltd Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate
CA2699328A1 (en) 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
ATE520689T1 (de) 2007-12-18 2011-09-15 Actelion Pharmaceuticals Ltd Aminotriazolderivate als alx-agonisten
US8236801B2 (en) * 2008-02-21 2012-08-07 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[2.2.1]heptane derivatives
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
US20110105491A1 (en) 2008-07-07 2011-05-05 Hamed Aissaoui Thiazolidine compounds as orexin receptor antagonists
WO2010038200A1 (en) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Oxazolidine compounds as orexin receptor antagonists
US20110212968A1 (en) 2008-10-14 2011-09-01 Hamed Aissaoui Phenethylamide derivatives and their heterocyclic analogues
US8710076B2 (en) 2008-10-21 2014-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
WO2010060471A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
JP2012509912A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
JP2012509910A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
CA2745420A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
AR074238A1 (es) 2008-12-02 2010-12-29 Glaxo Group Ltd Compuesto de n-{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4,1.0]hept-4-il]metil}-2-heteroarilamina, su uso para la preparacion de un medicamento util para el tratamiento de una enfermedad que requiere un antagonista del receptor de orexina humano y composicion farmaceutica que lo comprende
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
WO2010114978A1 (en) 2009-04-03 2010-10-07 Merck Sharp & Dohme Corp. Renin inhibitors
JP2012524760A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド オレキシンアンタゴニストとして使用される3−アザビシクロ[4.1.0]ヘプタン
NZ597453A (en) 2009-06-09 2013-03-28 Actelion Pharmaceuticals Ltd Fluorinated aminotriazole derivatives as alxr agonists
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
DK3093291T3 (da) 2009-10-23 2019-07-29 Janssen Pharmaceutica Nv Disubstituerede octahy-dropyrrolo [3,4-c]pyrroler som orexinreceptormodulatorer
US8680275B2 (en) 2009-10-23 2014-03-25 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
EP2526092B1 (en) 2010-01-19 2014-08-06 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
JP5744203B2 (ja) 2010-08-24 2015-07-08 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd オレキシン受容体拮抗薬としてのプロリンスルフォンアミド誘導体
BR112013008148A2 (pt) 2010-09-24 2016-08-09 Bristol Myers Squibb Co "inibidores do vírus da hepatite c".
CN103201261A (zh) 2010-11-10 2013-07-10 埃科特莱茵药品有限公司 用作为食欲素受体拮抗剂的内酰胺衍生物
EP2675801B1 (en) 2011-02-18 2015-04-08 Actelion Pharmaceuticals Ltd. Novel pyrazole and imidazole derivatives useful as orexin antagonists
MX343837B (es) 2011-11-08 2016-11-24 Actelion Pharmaceuticals Ltd Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida.
EP2855453B1 (en) 2012-06-04 2016-12-07 Actelion Pharmaceuticals Ltd. Benzimidazole-proline derivatives
WO2014057435A1 (en) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
CA2902135A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
UA119151C2 (uk) * 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
MA39163B1 (fr) 2013-12-03 2018-09-28 Idorsia Pharmaceuticals Ltd Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
JP6421185B2 (ja) * 2013-12-04 2018-11-07 イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd ベンゾイミダゾール−プロリン誘導体の使用

Also Published As

Publication number Publication date
CN104334544A (zh) 2015-02-04
KR101995683B1 (ko) 2019-07-02
HUE031753T2 (en) 2017-07-28
PT2855453T (pt) 2017-03-09
KR20180115804A (ko) 2018-10-23
CY1118735T1 (el) 2017-07-12
ZA201409422B (en) 2021-05-26
HRP20170351T1 (hr) 2017-04-21
EA201401351A1 (ru) 2015-05-29
MX354102B (es) 2018-02-13
AR091257A1 (es) 2015-01-21
MX2014014885A (es) 2015-03-05
AU2013273222B2 (en) 2017-11-02
FR22C1047I1 (fr) 2022-10-14
PH12014502540B1 (en) 2015-01-21
CA2873341A1 (en) 2013-12-12
NO2022044I1 (no) 2022-10-27
TW201400476A (zh) 2014-01-01
JP2015522558A (ja) 2015-08-06
US10329287B2 (en) 2019-06-25
US20170305897A1 (en) 2017-10-26
ES2617863T3 (es) 2017-06-20
KR20150023640A (ko) 2015-03-05
CN104334544B (zh) 2016-10-19
NL301197I1 (zh) 2022-10-05
EP2855453A1 (en) 2015-04-08
WO2013182972A1 (en) 2013-12-12
US11040966B2 (en) 2021-06-22
TW201600517A (zh) 2016-01-01
EA028046B1 (ru) 2017-10-31
EP2855453B1 (en) 2016-12-07
KR101689093B1 (ko) 2016-12-22
BR112014030173A8 (pt) 2017-12-26
KR20160088439A (ko) 2016-07-25
AU2013273222A1 (en) 2015-01-29
PH12014502540A1 (en) 2015-01-21
TWI570120B (zh) 2017-02-11
LTPA2022518I1 (zh) 2022-09-26
IL236024A0 (en) 2015-02-01
CA2873341C (en) 2018-01-02
HK1208449A1 (zh) 2016-03-04
SG10201702540UA (en) 2017-05-30
US20150166527A1 (en) 2015-06-18
LT2855453T (lt) 2017-02-27
IL236024A (en) 2016-09-29
SI2855453T1 (sl) 2017-05-31
CL2014003294A1 (es) 2015-03-20
SG11201408004SA (en) 2015-01-29
US9732075B2 (en) 2017-08-15
HUS2200040I1 (hu) 2022-09-28
EA201600366A1 (ru) 2016-08-31
NL301197I2 (nl) 2022-11-04
BR112014030173A2 (pt) 2017-06-27
PL2855453T3 (pl) 2017-05-31
DK2855453T3 (en) 2017-02-06
MY169986A (en) 2019-06-19
BR112014030173B1 (pt) 2022-10-04
JP5814491B2 (ja) 2015-11-17
TWI510481B (zh) 2015-12-01
EA029899B1 (ru) 2018-05-31
KR101946128B1 (ko) 2019-02-08
NZ703448A (en) 2017-07-28
US20190263797A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
FR22C1047I2 (fr) Derives de benzimidazole-proline
SMT201700065B (it) Derivato piridonico
DK2859055T3 (da) Polymercoatings
DK2825087T3 (da) Otoscanner
DK2839013T3 (da) Ikke-disruptiv-gen-targetering
CO6990736A2 (es) Pirrolidina-2-carboxamidas sustituídas
DK2873977T3 (da) Dobbeltdækker-rørdispenser
DE112012006109A5 (de) Okklusionsschienenanordnung
DK2854722T3 (da) Stomipose
AR092198A1 (es) Derivados de pirazolopirimidinas
CO7020919A2 (es) Derivados de tetrahidro-quinazolinona
DK2825157T3 (da) Aminosyrelipider
CO6960557A2 (es) Derivados de 2-yodo-imidazol
DK2831122T3 (da) Anthocyanidin-kompleks
DE112012006214T8 (de) Wulstringwickler
CO7020920A2 (es) Derivado de fenilazol sustituido
DE112012005566T8 (de) Seltenerdnanoverbundmagnet
FI20126082A (fi) Kaasunvaihtoventtiilijärjestely
DK2885638T3 (da) Molekylenet
DK2858657T3 (da) Feijoafrugtekstrakt
FI20126157A (fi) Laajentumistila
FI20125844A (fi) Talotekniikkamoduuli
ES1077590Y (es) Columbario
FR2999576B1 (fr) Derives de testosterone
DE102013212400A8 (de) Abdeckplattenstützbaugruppe